scholarly journals Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

JAMA Oncology ◽  
2020 ◽  
Vol 6 (8) ◽  
pp. 1241 ◽  
Author(s):  
Heikki Joensuu ◽  
Mikael Eriksson ◽  
Kirsten Sundby Hall ◽  
Annette Reichardt ◽  
Barbara Hermes ◽  
...  
Keyword(s):  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Survival Outcomes ◽  
Adjuvant Imatinib ◽  
Stromal Tumors

The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e23524-e23524
Author(s):  
Piotr Rutkowski ◽  
Marcin Zietek ◽  
Bozena Cybulska-Stopa ◽  
Joanna Streb ◽  
Stanislaw Gluszek ◽  
...  
Keyword(s):  
Clinical Trials ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Real World ◽  
Gastrointestinal Stromal Tumors ◽  
Disease Relapse ◽  
Adjuvant Imatinib ◽  
Stromal Tumors ◽  
Exon 9 ◽  
Exon 11

e23524 Background: The real-world data on outcomes of adjuvant therapy in high-risk gastrointestinal stromal tumors (GIST) are very limited. Methods: We have analyzed the data of 107 consecutive patients (52 male, 56 female) with GIST after resection treated with adjuvant imatinib (for planned 3 years with initial dose 400 mg daily, started not later than 4 months after operation) in 6 oncological centers in 2013-2018. All patients were required to have high risk of recurrence (at least 50% according to NCCN/AFIP criteria), known mutational status to exclude PDGFRA D842V mutants and KIT/PDGFRA-wild type cases from therapy. Median follow-up time was 24 months. Results: The most common primary localization of GIST was small bowel (63 patients; 59%), followed by the stomach (40 patients; 37%). The majority of GIST cases harbored exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. Thirty three patients (31%) finished 3-year adjuvant imatinib therapy as planned, 59 (55%) still continue therapy, 4 (4%) patients had finished adjuvant therapy prematurely due to toxicity, 6 (6%) due to disease progression on treatment and 5 (4%) due to other reasons. The disease relapse was detected in 16 patients, of them in 4 cases in exon 9 KIT mutants (36%), and 10 cases in patients with exon 11 KIT mutations (11%) [p < 0.05]. Estimated 4-year relapse-free survival (RFS) rate is 78%. Conclusions: The early results of adjuvant therapy with imatinib in routine practice outside clinical trials in high-risk mutation-drive GIST patients only confirm high efficacy of this therapy with better tolerability than in clinical trials. Moreover, overrepresentation of exon 9 KIT mutants in a group of patients with disease relapse may indicate that standard 400 mg dose in adjuvant treatment is not sufficient for prevention of disease relapse.

Adjuvant Imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: A median follow-up of 44 months

2011 ◽  
Vol 104 (7) ◽  
pp. 760-764 ◽  
Author(s):  
Wei-Zhong Jiang ◽  
Guo-Xian Guan ◽  
Hui-Shan Lu ◽  
Ying-Hong Yang ◽  
De-Yong Kang ◽  
...  
Keyword(s):  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
R0 Resection ◽  
Imatinib Treatment ◽  
Adjuvant Imatinib ◽  
Stromal Tumors

scholarly journals Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Rui Zhao ◽  
Yong Wang ◽  
Yuqian Huang ◽  
Yaping Cui ◽  
Lin Xia ◽  
...  
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Retrospective Cohort Study ◽  
Gastrointestinal Stromal Tumors ◽  
Retrospective Cohort ◽  
Adjuvant Imatinib ◽  
Stromal Tumors

scholarly journals Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0193048 ◽  
Author(s):  
Michaela Angelika Ihle ◽  
Sebastian Huss ◽  
Wiebke Jeske ◽  
Wolfgang Hartmann ◽  
Sabine Merkelbach-Bruse ◽  
...  
Keyword(s):  
Cell Cycle ◽  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Cell Cycle Regulators ◽  
Adjuvant Imatinib ◽  
Tp53 Mutations ◽  
Stromal Tumors

A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: A subdivision of the original high-risk group on the basis of outcome

Surgery ◽  
2007 ◽  
Vol 141 (6) ◽  
pp. 748-756 ◽  
Author(s):  
Hsuan-Ying Huang ◽  
Chien-Feng Li ◽  
Wen-Wei Huang ◽  
Tsung-Hui Hu ◽  
Ching-Nan Lin ◽  
...  
Keyword(s):  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Risk Group ◽  
High Risk Group ◽  
Stromal Tumors ◽  
Nih Consensus Criteria

The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

2020 ◽  
Author(s):  
Piotr Rutkowski ◽  
Marcin Ziętek ◽  
Bożena Cybulska-Stopa ◽  
Joanna Streb ◽  
Stanisław Głuszek ◽  
...  
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Routine Practice ◽  
Stromal Tumors

scholarly journals Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors

2019 ◽  
Vol Volume 12 ◽  
pp. 4713-4719 ◽  
Author(s):  
Yan-Shu Li ◽  
Wei Li ◽  
Qing-Sheng Zeng ◽  
Wei-Hua Fu
Keyword(s):  
High Risk ◽  
Treatment Regimen ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Postoperative Prognosis ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document